Found 12 articles
EicOsis LLC, a pharmaceutical startup developing a new class of oral non-narcotic analgesics based on inhibition of the soluble Epoxide Hydrolase (sEH) enzyme, announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to its lead drug candidate, EC5026, for the treatment of neuropathic pain.
EicOsis LLC, a pharmaceutical startup developing a new class of oral non-narcotic analgesics based on inhibition of the soluble Epoxide Hydrolase (sEH) enzyme, today announced initiation of dosing for the first human subject in a Phase 1 trial of EC5026, the company's lead product candidate for pain management.
EicOsis Awarded SBIR Grant from the NCI/NIH to Evaluate the Potential of Drug Candidate, EC5026, to Treat Cancer-associated Pain
EC5026 is an orally active potent small molecule that has been shown to be highly efficacious for pain relief of both inflammatory and neuropathic pain in a variety of animal species.
EicOsis receives $15MM grant from the National Institute of Drug Abuse to help fund trials of non-opioid pain therapy
The National Institute on Drug Abuse (NIDA) has awarded a grant to EicOsis LLC as part of the NIH initiative Helping to End Addiction Long-Term (HEAL Initiative) to support human clinical trials of a novel compound that has been found effective for the treatment of pain in preclinical animal studies
EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain
Phase 1 clinical trials for their drug candidate, EC5026, for the treatment of pain.
EicOsis Human Health is on track to initiate a first-in-human Phase 1a clinical trial in the third quarter of 2019 with its novel, non-opioid analgesic compound, EC5026.
EicOsis Human Health, located in Davis, CA, recently received a $5 million dollar investment from Open Philanthropy to support clinical trials on a novel, non-opioid, oral therapy for neuropathic and inflammatory pain.
ViroMed announced on November 7th that it has built a global team of experts to add momentum to the global development and commercialization of VM202 by recruiting Dr. William Schmidt, Dr. Cathryn Carroll, and Dr. Marie-Laure Nevoret.
Biotechnology Industry Organization (BIO) Announces Presenting Companies for 12th Annual BIO Investor Forum